SAN DIEGO, Jan 3, 2022 – Coastar Therapeutics Inc., an emerging biotech company focused on biological payload delivery technology for cancer immunotherapy and gene therapy, today announced that it is presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation. Eddie Y. Chung, CEO of Coastar Therapeutics, will be presenting the company at Biotech Showcase, and all registered attendees will have easy on-demand access to the presentation during the conference.

Coastar Therapeutics has developed an innovative cell membrane coating technology platform that enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease sites. The technology will lead to increased efficacy, reduced toxicity, lower cost and more applications in cancers and other diseases.

“With our proprietary cell membrane coating technology and industry-proven global partnerships business model, we will make a profound impact on many fields of medicine that utilize biologics as therapeutic agents, such as cancer immunotherapy, gene therapy, antibody, and vaccines. By ushering in a new paradigm of biological payload delivery, our technology will help millions of patients worldwide achieve better clinical outcome,” said Eddie Y. Chung, CEO of Coastar Therapeutics.

“As a pre-clinical stage biotech startup, we have made tremendous progress in the development of cell membrane coating technology for biological payloads. We have uncovered exciting science and obtained important data that will support upcoming IND-enabling studies with our partners”, said Han L. Lim, CSO of Coastar Therapeutics.

“Companies out there are developing incredibly promising therapies. We are ready to help them with our technology to safely deliver their therapies to tumors or sites of other diseases. We look forward to meeting these amazing companies at this year’s Biotech Showcase,” said Chongyang Luo, head of business development of Coastar Therapeutics.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Coastar Therapeutics will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 14th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT COASTAR THERAPEUTICS

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnS^TM technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites (YouTube link: https://youtu.be/4BMdkyJ09nM). The company is developing coatings for oncolytic viruses in cancer immunotherapy as well as for AAV in gene therapy.